Visine

Visine is an over-the-counter eye-care brand whose best-known products are drops intended to temporarily relieve visible eye redness and other forms of irritation. The brand was introduced in 1958 and is also identified in reference material by the name Vispring. Its original formulation used tetrahydrozoline hydrochloride, a vasoconstrictor that narrows superficial blood vessels in the eye and thereby reduces the appearance of redness for a limited period. Over time, Visine expanded beyond its original redness-relief product into a range of formulations aimed at different consumer needs. Depending on the market and product variant, the portfolio has included drops for allergy-related irritation, moisturizing products for dry eyes, artificial-tear-style products, and products designed for contact-lens users. Formulations may use different active ingredients, including oxymetazoline and naphazoline, rather than relying on a single brand-wide formula. Product suitability therefore depends on the specific package and active ingredient rather than on the Visine name alone. The brand changed corporate ownership twice in the period covered by the available reference material. Pfizer acquired Visine in 1999 as part of its consumer-health activities. In 2006, Johnson & Johnson acquired Visine together with Pfizer's broader consumer-healthcare portfolio. The brand is now produced by Kenvue, the consumer-health company that houses a number of brands formerly associated with Johnson & Johnson's consumer-health business. Visine's positioning is built around convenient, readily available symptom relief for common eye complaints, particularly redness and minor irritation. Its products are generally intended for short-term or label-directed use, not as a substitute for diagnosis or prescription treatment. Reference material describes possible stinging or burning after application and warns that prolonged or inappropriate use of some redness-relief products can produce rebound redness or extended dilation of ocular blood vessels. Certain variants may be unsuitable for contact-lens wearers or people with glaucoma, and persistent or medically significant eye symptoms may require professional care. The brand has also become associated with public-safety discussions about accidental or intentional ingestion. Tetrahydrozoline-containing eye drops can cause serious systemic poisoning when swallowed, including changes in blood pressure and body temperature, breathing problems, seizures, coma, and death. The popular claim that Visine ingestion merely causes diarrhea is described in the reference material as a debunked urban legend. These safety issues concern misuse or ingestion of particular formulations and should not be confused with the intended topical use of the products. Visine remains an active consumer eye-care brand, although exact product availability, formulation, labeling, and ownership presentation can vary by market.

Visine was introduced in 1958 as an over-the-counter eye-drop brand focused on the temporary reduction of eye redness. The original product used tetrahydrozoline hydrochloride, a vasoconstrictor that reduces the visibility of redness by constricting superficial blood vessels in the eye. This mechanism helped establish the brand's recognizable consumer proposition: a quick, convenient cosmetic and symptomatic response to red eyes. The brand subsequently developed a broader eye-care portfolio. In addition to the original redness-relief formulation, products associated with Visine have included variants for allergy-related irritation, moisturizing products for dry eyes, artificial-tear-style products, and products intended for people who wear contact lenses. Different variants use different active ingredients, including oxymetazoline and naphazoline. The range therefore represents a family of products rather than one universal formulation. Instructions, contraindications, and suitability for contact-lens use depend on the individual product. Corporate ownership changed during the late twentieth and early twenty-first centuries. Pfizer acquired Visine in 1999 as part of its consumer-health activities. In 2006, Johnson & Johnson acquired Visine along with Pfizer's entire consumer-healthcare portfolio. The brand later became part of Kenvue's consumer-health portfolio. Kenvue is the producer identified in the available reference material, although the precise legal ownership and distribution arrangements may differ by jurisdiction. Visine's consumer proposition has remained centered on self-care and convenience. Its products are sold as nonprescription remedies for temporary symptoms rather than as treatments for every cause of eye redness or discomfort. Reference material notes that some users may experience stinging or burning after application. It also describes a rebound effect in which prolonged use of certain redness-relief drops can make redness worse or leave blood vessels dilated for an extended period. For that reason, use is generally expected to follow the product label or medical advice. The history of the brand is also connected to safety education about misuse. Some products may be inappropriate for contact-lens wearers, while people with glaucoma or other underlying conditions may need professional advice before using particular formulations. Eye symptoms that persist or reflect an underlying disease may not respond adequately to an over-the-counter drop and may require prescription treatment or examination. A separate public-safety issue concerns ingestion. A widely circulated claim that drinking Visine produces harmless but incapacitating diarrhea has been characterized in the reference material as an urban legend. In reality, ingestion of tetrahydrozoline-containing drops can produce severe systemic toxicity, including hypothermia, blurred vision, nausea, vomiting, breathing difficulty, hypertension followed by hypotension, seizures, coma, and death. The brand has consequently appeared in discussions of poisoning and criminal cases, including allegations in South Carolina in 2018 and North Carolina in 2019. These incidents concern misuse of the product and do not describe its intended topical application. Visine remains an active eye-care brand under Kenvue. Its current portfolio and formulations are market-specific, and the available reference material does not establish a single global product lineup or a complete chronology of all launches.

• 2025

  Kenvue relocates its global headquarters

  [6]Kenvue Global Headquarters Openinginvestors.kenvue.com

  Kenvue officially opens its global headquarters in Summit, New Jersey.

• 2023

  Visine joins Kenvue

  [5]Kenvue Our Story and Leadership Teamkenvue.com

  Visine becomes part of Kenvue when Johnson & Johnson separates its consumer-health business into an independent company.

• 2006

  Johnson & Johnson acquires the brand

  [9]Johnson & Johnson buys Pfizer consumer-health unitnytimes.com

  Johnson & Johnson acquires Visine through its purchase of Pfizer’s consumer-health business.

• 1999

  Pfizer acquires Visine

  [1]Visineen.wikipedia.org

  Visine becomes part of Pfizer’s consumer-health portfolio.

• 1997

  Advertising dispute with Bausch & Lomb

  [7]Pfizer Visine advertising settlement with Bausch & Lombrbj.net

  Pfizer agrees to withdraw Visine A.C. advertisements challenged by Bausch & Lomb over allergy-relief claims.

• 1958

  Visine is introduced

  [1]Visineen.wikipedia.org

  Visine enters the market as an over-the-counter eye-drop brand focused on temporary relief of eye redness and minor irritation.

Accessible, mass-market over-the-counter eye care for temporary relief of redness, dryness, allergy-related itching and minor eye irritation. The brand combines fast-acting symptom relief with a broad portfolio of lubricating and multi-symptom products.

• Redness-relief eye drops · 1958

  VISINE Original Redness Relief

  The brand’s traditional redness-relief line is designed to temporarily reduce eye redness caused by minor irritation. U.S. labeling identifies tetrahydrozoline hydrochloride as the active redness-relief ingredient in the original formulation. These products are positioned for occasional, short-term symptom relief rather than treatment of an underlying eye disease.

• Redness-relief eye drops

  VISINE Red Eye Comfort

  A current red-eye product positioned for fast-acting relief of redness associated with minor eye irritation. It represents the brand’s core proposition while using contemporary packaging and portfolio architecture to distinguish red-eye relief from Visine’s lubricant and allergy products.

• Allergy eye drops

  VISINE Allergy Eye Relief Multi-Action

  An antihistamine and redness-reliever product intended for itchy, red eyes caused by common seasonal or environmental allergens such as pollen, grass, ragweed and animal dander. U.S. labeling identifies naphazoline hydrochloride and pheniramine maleate as active ingredients.

• Allergy and itchy-eye relief

  VISINE AC Itchy Eye Relief

  A product line aimed at itchy and watery eyes, with an astringent and redness-relief positioning. It extends Visine beyond the purely cosmetic red-eye proposition into symptom relief associated with irritation and allergy-related discomfort.

• Lubricating eye drops

  VISINE Dry Eye Relief

  A family of lubricant eye drops designed to moisturize and soothe dry, tired or irritated eyes. The line includes products for everyday dryness, screen-related discomfort and longer-lasting comfort. These products are positioned as lubricants rather than substitutes for redness-relief formulas.

• Multi-symptom eye drops

  VISINE Red Eye Total Comfort Multi-Symptom

  A multi-symptom range intended to address combinations of red, itchy and dry-eye symptoms. Its role in the portfolio is to offer a single product for consumers who experience several forms of minor eye discomfort at the same time.

• Artificial tears and lubrication

  Visine Tears

  An earlier or market-specific Visine family associated with lubrication and artificial-tear support. The line reflects the brand’s historical expansion from redness relief into products intended to soothe dry and irritated eyes.

• 1999Gets the Red Out

  United States

  A long-running advertising platform centered on Visine’s ability to make red or bloodshot eyes appear clearer. The campaign helped establish the brand as a shorthand for fast redness relief and connected product performance with an immediately visible consumer benefit.

  Outcome. The platform became one of Visine’s most recognizable pieces of brand equity and continued to be associated with the brand for decades.

  Source
• 1997Visine A.C. allergy-relief advertising

  United States

  Pfizer promoted Visine A.C. with claims positioning it as a broad over-the-counter allergy-relief product. Bausch & Lomb challenged the advertising, arguing that the product’s FDA authorization did not support the breadth of the claims.

  Outcome. Pfizer agreed to permanently withdraw the challenged advertisements as part of a settlement; it admitted no wrongdoing and other settlement terms were not disclosed.

  Source

• 2025

  Kenvue establishes new global headquarters in SummitStrategy

  Background

  Kenvue relocated its global corporate center from its interim headquarters in Skillman, New Jersey.

  Action taken

  Kenvue opened a new global headquarters and science-and-innovation campus in Summit, New Jersey.

  Aftermath

  The relocation confirmed Kenvue’s current United States headquarters and provided a new corporate and research base for the company’s brands, including Visine.

  Source

• 2023

  Transfer to Kenvue after consumer-health separationM&A

  Background

  Johnson & Johnson separated its consumer-health operations into a standalone company to create an independent consumer-health business.

  Action taken

  Visine became part of Kenvue, which began trading as an independent public company in May 2023.

  Aftermath

  The brand continued under a dedicated consumer-health company with a portfolio spanning self care, skin health and beauty, and essential health.

  Source

• 2006

  Johnson & Johnson acquisition of Pfizer consumer healthM&A

  Background

  Johnson & Johnson sought to expand its consumer-health business through the purchase of Pfizer’s consumer-health portfolio.

  Action taken

  Johnson & Johnson acquired Visine together with Pfizer’s consumer-health business.

  Aftermath

  Visine joined a larger portfolio of consumer medicines, oral-care, skin-care and personal-care brands.

  Transaction value. Approximately $16.6 billion (2006 acquisition)

  Source

• 1999

  Pfizer acquisition of VisineM&A

  Background

  Visine was an established consumer eye-care brand with strong recognition in the over-the-counter market.

  Action taken

  Pfizer acquired the brand and incorporated it into its consumer-health portfolio.

  Aftermath

  The acquisition gave Visine access to Pfizer’s broader consumer-health infrastructure and international commercial organization.

  Source

• 1997

  Withdrawal of challenged Visine A.C. advertisementsOther

  Background

  Bausch & Lomb sued Pfizer, arguing that Visine A.C. advertisements made allergy-relief claims broader than the product’s regulatory authorization.

  Action taken

  Pfizer agreed to stop airing the challenged television advertising as part of a settlement.

  Aftermath

  The dispute underscored the need to align over-the-counter eye-care advertising with approved product indications.

  • Bausch & Lomb — Bausch & Lomb characterized the settlement as a victory for more accurate consumer information and promoted its Opcon-A product as an alternative.

  Source

1. 1Visineen.wikipedia.org
2. 2VISINE Eye Drops and Relief Productsvisine.com
3. 3VISINE official websitevisine.com
4. 4VISINE Allergy Eye Relief FDA labelaccessdata.fda.gov
5. 5Kenvue Our Story and Leadership Teamkenvue.com
6. 6Kenvue Global Headquarters Openinginvestors.kenvue.com
7. 7Pfizer Visine advertising settlement with Bausch & Lombrbj.net
8. 8Pfizer: Gets the Red Out campaignwarc.com
9. 9Johnson & Johnson buys Pfizer consumer-health unitnytimes.com